Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Guggenheim

Health Care Fund Class A (RYHEX)

Ticker RYHEX · · Holdings as of Jun 30, 2026

Expense ratio
1.64%$164/yr per $10k
5-yr return
+3.9%annualized
1-yr return
+8.7%as of Dec 2025
Net assets
$19.4Mall share classes
Holdings
135

Bottom line

Is RYHEX a good fund? The bottom line

RYHEX is the Class A share class of Health Care Fund, an actively managed health care sector mutual fund from Guggenheim.

It charges 1.64% — about $164 a year on every $10,000 invested, more expensive than 84% of health care sector funds we track.

It returned +8.7% over one year, +3.9% a year over five years, +7.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $19.4 million in net assets and 135 holdings, its largest position is Eli Lilly & Company (3.6%) and the top 10 make up 20.6% of the portfolio.

This share class carries a front-end sales charge of up to 4.75%; a no-load class or ETF alternative can avoid it.

The closest lower-cost alternative we found is XLV (0.08%, 79% top-holdings overlap).

What to watch

  • Expensive for its category (1.64%)
  • Front-end sales load up to 4.75%
  • 12b-1 marketing fee of 0.25% a year
  • Small fund ($19.4 million) — small funds are likelier to close
  • High turnover (244% a year) can mean more taxable distributions

Updated Nov 19, 2026

What RYHEX invests in

The Health Care Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the health care industry (Health Care Companies).

Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Health Care Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor. The Fund may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. Health Care…

From the fund's prospectus (filed Jul 29, 2026).

RYHEX performance

Average annual total returns
1 yr5 yr10 yr
RYHEX+8.7%+3.9%+7.1%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full RYHEX performance history →

What RYHEX costs

On a $10,000 investment, RYHEX's 1.64% expense ratio costs about $164 a year. The prospectus estimates $2,374 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full RYHEX fee table →

RYHEX top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY3.63%
2Johnson & Johnson JNJ2.88%
3Abbvie Inc ABBV2.52%
4Unitedhealth Group Inc UNH2.22%
5Merck & Company Inc MRK2.04%
6Thermo Fisher Scientific Inc TMO1.61%
7Amgen Inc AMGN1.56%
8Abbott Laboratories ABT1.42%
9Gilead Sciences Inc GILD1.39%
10Vertex Pharmaceuticals Inc VRTX1.34%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 20.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to RYHEX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%79% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%80% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%81% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%76% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%64% Compare
SchwabSWHFX Schwab Health Care Fund0.8%66% Compare

More funds like RYHEX →

RYHEX FAQ

What is the expense ratio of RYHEX?
RYHEX's expense ratio is 1.64%, which works out to about $164 a year for every $10,000 invested. The prospectus estimates total costs of $2,374 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RYHEX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.64%); front-end sales load up to 4.75%; 12b-1 marketing fee of 0.25% a year; small fund ($19.4 million) — small funds are likelier to close; high turnover (244% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does RYHEX hold?
RYHEX's largest holdings are Eli Lilly & Company (3.6%), Johnson & Johnson (2.9%), Abbvie Inc (2.5%), Unitedhealth Group Inc (2.2%), Merck & Company Inc (2.0%). It holds 135 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RYHEX's 5-year return?
RYHEX returned +3.9% a year over the five years ending Dec 31, 2025, and +7.1% a year over ten years. Past performance does not guarantee future results.
Does RYHEX have a sales load?
Yes. RYHEX has a maximum front-end sales charge of 4.75%.
What is a cheaper alternative to RYHEX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 79% with RYHEX and charges 0.08%.
Who manages RYHEX?
RYHEX is offered by Guggenheim through Rydex Series Funds.